Global expansion Mirxes’ rapid international footprint across Singapore, USA, Japan, and China, plus a global sales network, signals strong potential for regional partnerships, distributorships, and co-development deals in new markets and clinical segments.

Early cancer focus With GASTROClear and an expanding pipeline for lung, thyroid, colorectal, breast, liver, and ovarian cancers, there are multiple upsell opportunities for adjacent cancer screening tests, longitudinal risk assessment programs, and multi-cancer early detection collaborations.

Home and clinical integration Recent at-home screening kit initiatives in Thailand and ongoing proficiency in clinical diagnostics create opportunities to sell integrated at-home-to-clinic care pathways, telehealth partnerships, and payer-aligned screening programs.

Strengthening partnerships Strategic financing activity, IPO momentum, and collaboration with government-backed and academic institutes (A*STAR origins, Fortitude COVID test network) indicate readiness for co-development, technology licensing, and joint ventures with larger healthcare and biotech players.

Financial scale & demand Substantial revenue range and recent $349M funding, plus high-profile IPO funding rounds, imply buyers and investors are receptive to large-scale deployment of diagnostic tests, manufacturing capacity expansions, and long-term service agreements.